ASTX727 and Retifanlimab for advanced Merkel cell carcinoma
Part of Cancer, Infections clinical trials.
This trial tests combining two drugs—ASTX727 (an oral pill) and retifanlimab (an immunotherapy)—for people with advanced Merkel cell carcinoma that has grown despite previous immunotherapy. The goal is to see if this combination can work better than previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced Merkel cell carcinoma that can't be removed with surgery.
- You have already tried an immunotherapy drug (like Keytruda or Opdivo) and your cancer got worse on it.
- You have not had treatment with a hypomethylating agent (like azacitidine or decitabine) before.
- You are not currently having an infection that needs treatment, and you are not on high-dose steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether peptide receptor radionuclide therapy (targeted radiation) combined with immunotherapy (pembrolizumab) can shrink Merkel cell cancer after it has grown despite anti–PD-1/L1 treatment. It may help people whose cancer has specific receptors that make them eligible for the targeted radiation.
This trial tests a combination of two immunotherapy drugs, nivolumab and relatlimab, before surgery for Merkel cell carcinoma that can be removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests the combination of pembrolizumab (an immunotherapy) with standard chemotherapy (cisplatin or carboplatin plus etoposide) in people with advanced Merkel cell carcinoma who haven't had treatment before. The goal is to see if this combination improves outcomes.
This trial tests pembrolizumab (an immune therapy) given before surgery to shrink Merkel cell carcinoma and improve outcomes. Participants also have extra tumor biopsies to study biomarkers, which may help explain who benefits most.
This trial tests a new drug called CRD3874-SI for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and can shrink tumors.
This Phase 2 trial tests a specific radiation timing/dose schedule for Merkel cell carcinoma (MCC), a rare and aggressive skin cancer. It may help by improving control of the cancer after surgery, especially in higher-risk cases (like lymph nodes).
Hear when a new Merkel Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.